August Krogh / CWS mini symposium

13:00-13:55: Professor Hadi Al-Hasani
13:55-14:25: Dr. Benjamin L. Parker, PhD
Short break
14:30-15:00: Dr. Adam Rose, PhD
15:00-15:55: Professor Mark Febbraio
16:00-17:00: Reception for all participants

Genetic Regulation of Proteome and Lipidome Diversity and its Contribution to Hepatic Steatosis

v/ Dr. Benjamin L. Parker, PhD, NHMRC Early Career Fellow, Metabolic Systems Biology Group, Charles Perkins Centre, School of Life and Environmental Science, The University of Sydney, Australia.


Hepatosteatosis is rapidly becoming one of the primary morbidities in developed countries, owing to its causal effects in diseases including type 2 diabetes (T2D), cardiovascular disease (CVD), liver cirrhosis and hepatocellular carcinoma (HCC). Unfortunately, our understanding of the contributing metabolic pathways that initiate and progress hepatosteatosis to subsequent complications is still poorly understood.

Therefore, further studies are required to define these pathways to better manage and treat hepatosteatosis.  Here, we take advantage of recent developments in “omics” technologies to perform high resolution proteomics (>5000 proteins) and quantitative lipidomics (>300 lipids) on livers (n=3) from 107 strains of inbred, genetically diverse mice from the hybrid mouse diversity panel (HMDP).

Subsequent analyses demonstrate a striking 27-fold difference in hepatic triglyceride content across the strains in 8-week old, male mice on a normal chow diet. This was associated with marked, yet specific alterations in the hepatic proteome and lipidome which, once integrated with genomic and phenomic datasets, has allowed us to define several dysregulated pathways associated with genetically predisposed hepatosteatosis.

Relevant papers
Research profile

Dr Parker completed his PhD with A/Prof. Stuart Cordwell and Prof. Martin Larsen between the University of Sydney and the University of Southern Denmark developing proteomic and mass spectrometry (MS) assays applied to study signal transduction and metabolism during ischemia. He was the receipt of multiple awards most notably the European Proteomics Association (EuPA) Young Investigator of the Year Award (2010) and the Royal Society of NSW Award (2011).

In 2013 he was awarded an Early Career Fellowship with Prof. David James at the Garvan Institute of Medical Research where he was also appointed as the manager of the Biological Mass Spectrometry Unit. He recently moved to the newly established Charles Perkins Centre at the University of Sydney and is involved in the establishment of Australia's largest mass spectrometry facilities.

In 2015, he spent 6 months in Dr. Paul Gregorevic’s laboratory at the Baker IDI Heart and Diabetes Institute in Melbourne where he gained experience in gene therapy techniques with a focus on the development of adeno-associated viruses for the transduction of mouse skeletal muscle and, a number of muscle physiology techniques. He currently managers a research team under Prof. David James at the Charles Perkins Centre combining gene therapy and MS to study biochemistry relating to exercise and metabolic disease.


19 May 2017

13:00-13:55: Professor Hadi Al-Hasani
13:55-14:25: PhD Benjamin L. Parker
Short break
14:30-15:00: PhD Adam Rose
15:00-15:55: Professor Mark Febbraio
16:00-17:00: Reception for all participants


Auditorium 1, August Krogh Building, Universitetsparken 13, DK-2100 Copenhagen


Participation is free, but please register here.

For PhD students

PhD students participating in August Krogh seminars receive 0,2 ECTS per seminar


Jonas Møller Kristensen,, mobile +45 6092 1309

Upcoming seminars

Link to other upcoming seminars.